JP Morgan maintains Overweight on Insmed, cuts target to $179
JP Morgan analyst Jessica Fye maintained an Overweight rating on Insmed (NASDAQ: INSM) and lowered the price target to $179 from $180.
*this image is generated using AI for illustrative purposes only.
JP Morgan analyst Jessica Fye maintained an Overweight rating on Insmed (NASDAQ: INSM) while adjusting the stock's price target. The firm reduced the target to $179 from the previous $180. The rating update reflects a continued positive outlook on the stock despite the minor adjustment in the valuation target.
Rating and Target Details
The decision to keep the Overweight rating suggests confidence in Insmed's performance potential relative to the broader market. The $1 reduction in the price target brings the new valuation to $179.
What factors could drive Insmed's stock to surpass the revised $179 price target?
How might upcoming clinical trial results influence Insmed's market performance?
What competitive pressures could impact Insmed's ability to maintain its Overweight rating?
15
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
